Lifecore Biomedical signs commercial site transfer deal with global pharma company

PUBT · 2d ago
Lifecore Biomedical signs commercial site transfer deal with global pharma company
  • Lifecore Biomedical signed an agreement to transfer a commercially marketed injectable drug product into its pipeline for future commercial manufacturing.
  • Work covers technical transfer services to support commercial production for a global pharmaceutical customer.
  • Program expected to generate commercial revenue in 2028.
  • Deal adds Lifecore’s seventh late-stage commercial program, bringing the 2026 pipeline additions to 11 programs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifecore Biomedical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020705PRIMZONEFULLFEED9820023) on September 02, 2026, and is solely responsible for the information contained therein.